TAMMY H YOUNG M.D. NPI 1013911668

NPI Details

Tammy H Young, M.D. is a medical oncology internal medicine in Jackson, MS with 24 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Tammy H Young, M.D. NPI is 1013911668. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE
Graduation Year:2002

The provider's business location address is:

1227 N STATE ST
STE 101
JACKSON, MS
ZIP 39202-002
Phone: (601) 355-2485
Fax: (601) 353-1463

The NPI 1013911668 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, levoleucovorin, not otherwise specified, 0.5 mg (HCPCS:J0641)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, rituximab 10 mg and hyaluronidase (HCPCS:J9311)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg (HCPCS:Q5117)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, rituximab, 10 mg (HCPCS:J9312)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Ferritin (blood protein) level (HCPCS:82728)
• Unclassified drugs (HCPCS:J3490)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Folic acid level, serum (HCPCS:82746)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Influenza vaccine, quadrivalent derived from recombinant dna (HCPCS:90682)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Collection of blood sample from implanted device (HCPCS:36591)
• Vitamin d-3 level (HCPCS:82306)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Drawing of blood for a medical problem (HCPCS:99195)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and (HCPCS:G0180)
• Red blood count, automated test (HCPCS:85045)
• Magnesium level (HCPCS:83735)

The enumeration date for this NPI number is 6/10/2005 and was last updated on 12/8/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.